GenMark Diagnostics : GNMK January 2021 Investor Presentation

GenMark Diagnostics

Delivering Diagnostics that Improve Patient Care

January 2021

© Copyright 2021 GenMark Diagnostics, Inc. All rights reserved

Forward-Looking Statement

This presentation contains forward-looking statements about GenMark Diagnostics, Inc. These statements involve known and unknown risks that relate to the Company's future events or future financial performance and the actual results could differ materially from those discussed in this presentation. Factors that may cause the Company's actual results to differ materially from those discussed in the presentation, include:

• our ability to achieve our preliminary and projected financial and operational performance guidance;
• our ability to secure enduring revenue streams extending beyond the current COVID-19 pandemic;
• our failure to scale our manufacturing operations to sufficiently support our anticipated future growth;
• our failure to drive manufacturing efficiencies and manufacturing cost improvements to achieve our gross margin projections;
• disruptions to our manufacturing operations and/or supply chain;
• our ability to successfully obtain regulatory clearance for our ePlex panels, and achieve our ePlex test menu adoption, consistent with our expectations;
• the refusal of third-party payors to reimburse the Company's customers for use of diagnostic systems and tests;
• the loss of the Company's most significant customers;
• increases in the Company's projected expenditures on sales and marketing, research and development and administrative activities;
• less than anticipated growth in the market for diagnostic testing generally and for the tests the Company is developing or may develop in the future;
• changes in the regulatory environment which may adversely impact the commercialization of the Company's new products and result in significant additional capital expenditures;
• failure to enter into or maintain successful strategic alliances, which may delay the development or commercialization of the Company's products or may result in significant additional expenditures;
• failure to obtain sufficient funding for the continued development and commercialization of the Company's products;
• inability to attract or retain skilled personnel for the Company's product development and commercialization efforts; and
• inability to protect the Company's intellectual property and operate the Company's business without infringing upon the intellectual rights of others, which could result in litigation and significant expenditures.

Additional risks and uncertainties relating to the Company and its business can be found in the "Risk Factors" section of GenMark's most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and other filings with the United States Securities and Exchange Commission. The forward-looking statements contained in this presentation represent the Company's estimates and assumptions only as of the date of this presentation and the Company undertakes no duty or obligation to update or revise publicly any forward-looking statements contained in this presentation as a result of new information, future events, or changes in the Company's expectations.

2 © Copyright 2021 GenMark Diagnostics, Inc. All rights reserved

2020 Highlights

Preliminary 2020 results significantly fast forwarded the business Financial & Operational results

95%	Revenue Growth	265	ePlex analyzers placed in
2020

$10M	Anticipated Cash Flow	>75%	Increase in monthly ePlex
From Operations
		consumable capacity

3 3 © Copyright 2021 GenMark Diagnostics, Inc. All rights reserved

Syndromic Testing Provides Highest Clinical Value

Rapid, accurate, and actionable diagnostics are needed for effective management of high-risk patients

Many potential bugs cause the same symptoms

Syndromic Testing is the solution

Simple, rapid and actionable

• Enhance lab efficiency
• Avoid reflex/repeat testing

Effectively manage patient care

• Reduce patient time-to-result
• Rule in and rule out many bugs

Improve hospital quality and cost

• Improve Antibiotic Stewardship
• Reduce length of stay

4 © Copyright 2021 GenMark Diagnostics, Inc. All rights reserved